Skip to main content
TipRanks
Go Ultimate75% OFF

Gufic Biosciences Limited (GUFICBIO) AI Stock Analysis

0 Followers
IN:GUFICBIO

Gufic Biosciences Limited

(NSE:GUFICBIO)

Select Model
Rating:61Neutral
Price Target:INR 512.00â–²(20.73% Upside)
Action:reiterated
Date:09/30/26

Moderate financial performance driven by balance sheet strength but offset by profit declines and cash volatility is the primary factor; bullish technical momentum provides support while high valuation weighs on the score.

Positive Factors
Revenue GrowthRevenue growth re-accelerated in FY2026 after a flat prior year, indicating renewed demand for the company’s pharmaceutical portfolio. Although growth has been uneven, higher sales provide a base for operating leverage and support continued investment in formulations and specialty therapies.
Negative Factors
Weak Cash ConversionThe sharp deterioration in operating cash flow and negative free cash flow weakens the quality of reported earnings. Poor cash conversion can constrain internally funded expansion, increase reliance on financing, and reduce flexibility to absorb operational pressures over the coming quarters.

Gufic Biosciences Limited (GUFICBIO) vs. iShares MSCI India ETF (INDA)

-30%-20%-10%0%10%20%30%40%IN:GUFICBIO+19.61%INDA-5.07%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 42.18B
Dividend Yield
0.02%
Average Volume (3M)
6,617
Price to Earnings (P/E)
57.7
Beta (1Y)
0.64
Revenue Growth
16.70%
EPS Growth
18.73%
Country
India
Employees
1,491
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Gufic Biosciences Limited Business Overview & Revenue Model

Company Description

Gufic Biosciences Limited is an Indian enterprise dedicated to the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic medications, and related support services. The company's API and bulk drug offerings include antifunga...

Gufic Biosciences Limited Financial Statement Overview

Summary

Solid balance sheet growth and manageable debt provide stability, but declining profitability, margin compression, and cash flow volatility pose risks.

Income Statement

55Neutral

Balance Sheet

75Positive

Cash Flow

45Neutral
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue9.81B9.44B8.20B8.07B6.91B7.79B
Gross Profit4.52B3.40B2.97B4.07B3.51B3.56B
EBITDA1.66B1.54B1.38B1.48B1.37B1.50B
Net Income734.57M642.15M696.50M861.36M797.05M958.40M
Balance Sheet
Total Assets013.42B11.69B10.93B8.61B5.21B
Cash, Cash Equivalents and Short-Term Investments621.86M762.17M290.22M11.37M286.02M116.08M
Total Debt04.05B3.36B3.33B3.34B643.87M
Total Liabilities-6.65B6.77B5.68B5.60B5.13B2.52B
Stockholders Equity6.65B6.65B6.01B5.33B3.48B2.69B
Cash Flow
Free Cash Flow434.82M-180.11M270.96M-1.20B-2.14B187.86M
Operating Cash Flow591.15M131.71M1.03B-74.57M-265.87M1.06B
Investing Cash Flow-152.90M-319.73M-717.09M-1.02B-1.91B-945.89M
Financing Cash Flow150.53M652.67M-163.26M823.81M2.34B-62.44M

Gufic Biosciences Limited Technical Analysis

Technical Analysis SentimentNegative
Last Price424.10

Price Trends

50DMA426.47Negative
100DMA414.08Positive
200DMA360.43Positive

Market Momentum

MACD8.45Negative
RSI46.98Neutral
STOCH36.72Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:GUFICBIO, the sentiment is Negative. The current price of 424.10 is below the 20-day moving average (MA) of 429.64, below the 50-day MA of 426.47, and above the 200-day MA of 360.43, indicating a neutral trend. The MACD of 8.45 indicates Negative momentum. The RSI at 46.98 is Neutral, neither overbought nor oversold. The STOCH value of 36.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:GUFICBIO.

Gufic Biosciences Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

IN:GUFICBIO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:BLISSGVSIN:BLISSGVS65NeutralINR 71.70B45.00―0.22%24.87%46.37%
IN:GUFICBIOIN:GUFICBIO61NeutralINR 42.53B57.68―0.02%16.70%18.73%
IN:MOREPENLABIN:MOREPENLAB55NeutralINR 50.55B26.93―0.22%30.20%91.17%
IN:ORCHPHARMAIN:ORCHPHARMA55NeutralINR 57.21B559.03――10.83%-89.83%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
IN:UNICHEMLABIN:UNICHEMLAB51NeutralINR 34.01B9.95――6.44%283.10%
IN:INDOCOIN:INDOCO43NeutralINR 22.26B71.18―0.08%10.75%―

* Healthcare Sector Average

Performance Comparison

0%100%200%300%IN:GUFICBIOIN:BLISSGVSIN:INDOCOIN:MOREPENLABIN:ORCHPHARMAIN:UNICHEMLABDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:GUFICBIO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:GUFICBIOGufic Biosciences Limited424.1070.9920.10%
IN:BLISSGVSBliss Gvs Pharma Limited674.30515.11323.58%
IN:INDOCOIndoco Remedies Limited241.15-16.88-6.54%
IN:MOREPENLABMorepen Laboratories Limited92.2548.31109.96%
IN:ORCHPHARMAOrchid Pharma Limited955.4089.6510.36%
IN:UNICHEMLABUnichem Laboratories Limited483.0515.253.26%

Gufic Biosciences Limited Corporate Events

Gufic Biosciences Receives USFDA Observations After Pre-Approval Inspection at Indore Plant

Oct 23, 2026

Gufic Biosciences Limited has disclosed that the U.S. Food and Drug Administration recently conducted a pre-approval inspection at its manufacturing facility in Indore, Madhya Pradesh, over the period from October 15 to October 23, 2026. The inspecti...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 30, 2026